BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24631944)

  • 21. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
    Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
    Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of prognostic biomarkers associated with stromal cell infiltration in muscle-invasive bladder cancer by bioinformatics analyses.
    Li P; Cao J; Li J; Yao Z; Han D; Ying L; Wang Z; Tian J
    Cancer Med; 2020 Oct; 9(19):7253-7267. PubMed ID: 32786144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer.
    Yang D; Ma Y; Zhao P; Ma J; He C
    Biomed Pharmacother; 2019 Dec; 120():109433. PubMed ID: 31568988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features.
    Li W; Wang Y; Tan S; Rao Q; Zhu T; Huang G; Li Z; Liu G
    Med Sci Monit; 2018 Oct; 24():7178-7185. PubMed ID: 30296252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
    Bunch B; Krishnan N; Greenspan RD; Ramakrishnan S; Attwood K; Yan L; Qi Q; Wang D; Morrison C; Omilian A; Bshara W; Pili R; Trump DL; Johnson C; Woloszynska A
    Cell Cycle; 2019 Sep; 18(17):2055-2066. PubMed ID: 31318640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and Predictive Value of O
    Zhang J; Zhu Y; Wang Y; Fu Q; Xie H; Liu Z; Fu H; Cao Y; Xu J; Dai B
    Ann Surg Oncol; 2018 Jan; 25(1):342-348. PubMed ID: 29116491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal Growth Factor Receptor and Ki-67 as Predictive Biomarkers Identify Patients Who Will Be More Sensitive to Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Radical Nephroureterectomy.
    Long X; Zu X; Li Y; He W; Hu X; Tong S; Wang Z; Chen M; Qi L
    PLoS One; 2016; 11(11):e0166884. PubMed ID: 27870887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction of an Immune-Associated Gene-Based Signature in Muscle-Invasive Bladder Cancer.
    Shen C; Xu T; Sun Y; Wang L; Liang Z; Niu H; Jiao W; Wang Y
    Dis Markers; 2020; 2020():8866730. PubMed ID: 33456631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Goodspeed A; Jean A; Costello JC
    Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of S100A8, S100A9 and calprotectin levels in bladder cancer.
    Yasar O; Akcay T; Obek C; Turegun FA
    Scand J Clin Lab Invest; 2017 Oct; 77(6):437-441. PubMed ID: 28609200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility and outcomes in muscle invasive bladder cancer patients.
    Kang HW; Song PH; Ha YS; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Moon SK; Kim WJ
    Eur J Cancer; 2013 Sep; 49(14):3010-9. PubMed ID: 23810248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
    Lodde M; Mian C; Mayr R; Comploj E; Trenti E; Melotti R; Campodonico F; Maffezzini M; Fritsche HM; Pycha A
    Int J Urol; 2014 Oct; 21(10):968-72. PubMed ID: 24947145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer.
    Jiang X; Du L; Duan W; Wang R; Yan K; Wang L; Li J; Zheng G; Zhang X; Yang Y; Wang C
    Oncotarget; 2016 Jun; 7(24):36733-36742. PubMed ID: 27167342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical importance of S100A9 in osteosarcoma development and as a diagnostic marker and therapeutic target.
    Liu Y; Luo G; He D
    Bioengineered; 2019 Dec; 10(1):133-141. PubMed ID: 31055998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin.
    Zhang X; Zhang Y; Liu X; Fang A; Li P; Li Z; Liu T; Yang Y; Du L; Wang C
    PLoS One; 2015; 10(11):e0143441. PubMed ID: 26599571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of cadherin-11 for subsequent recurrence and progression in non-muscle invasive bladder cancer.
    Chen MK; Chen ZJ; Xiao KH; Qin ZK; Ye YL; Wen WJ; Bian J; Xue KY; Zhou QZ; Guo WB; Zhou JH; Xia M; Li X; Liu CD
    Jpn J Clin Oncol; 2020 Apr; 50(4):456-464. PubMed ID: 31894237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.
    Iliev R; Kleinova R; Juracek J; Dolezel J; Ozanova Z; Fedorko M; Pacik D; Svoboda M; Stanik M; Slaby O
    Tumour Biol; 2016 Oct; 37(10):13385-13390. PubMed ID: 27460088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR.
    Wang A; Jiang A; Gan X; Wang Z; Huang J; Dong K; Liu B; Wang L; Chen M
    Biomed Res Int; 2020; 2020():6665974. PubMed ID: 33426060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.